Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Aurora Spine Corporation is a U.S.-based medical device company operating in the spinal surgery and orthopedic implant industry. The company designs, develops, and commercializes minimally invasive spinal implant systems intended to improve surgical efficiency and patient outcomes. Its primary revenue is generated through the sale of proprietary spinal implants and related instrumentation to hospitals, ambulatory surgery centers, and spine surgeons.
The company is positioned around minimally invasive spine (MIS) technologies, emphasizing simplified implantation, reduced operative time, and lower procedural costs. Aurora Spine was founded in 2011 by Trent J. Northcutt and has evolved from a development-stage company into a commercial-stage medical device manufacturer with an expanding product portfolio and growing international distribution network. The company’s common shares trade on the U.S. OTC Markets under the ticker ASAPF.
Business Operations
Aurora Spine’s operations are centered on a single operating segment focused on spinal implant systems, encompassing product design, regulatory clearance, manufacturing oversight, and commercialization. Revenue is generated primarily through direct sales in the United States and through independent distributors in international markets. The company’s product portfolio includes interbody fusion devices, fixation systems, and motion-preservation implants designed for cervical, thoracic, and lumbar spine procedures.
The company controls its proprietary implant designs and intellectual property while leveraging third-party manufacturing partners for production. Aurora Spine operates without large-scale manufacturing facilities, allowing it to maintain a relatively asset-light cost structure. Public disclosures do not indicate the existence of majority-owned operating subsidiaries or joint ventures; data inconclusive based on available public sources regarding material equity investments in other entities.
Strategic Position & Investments
Aurora Spine’s strategic direction emphasizes organic growth through new product development, expanded regulatory clearances, and increased penetration of minimally invasive spine procedures. The company regularly invests in research and development to enhance its implant portfolio, focusing on differentiated designs intended to simplify surgical workflows and reduce operating room time.
The company has historically pursued targeted acquisitions of intellectual property and product lines rather than large corporate acquisitions. No transformative mergers or acquisitions have been disclosed in recent public filings. Aurora Spine’s strategy also includes expanding its surgeon education programs and strengthening distributor relationships to increase adoption of its technologies in competitive spine markets.
Geographic Footprint
Aurora Spine is headquartered in Carlsbad, California, which serves as the company’s primary corporate, regulatory, and commercial operations hub. The majority of its revenue is generated in the United States, where it maintains direct sales coverage and distributor relationships.
Internationally, the company has established market presence through distribution agreements across Europe, the Middle East, Asia-Pacific, and parts of Latin America. While international sales represent a smaller portion of total revenue compared to domestic operations, global expansion remains a stated focus, particularly in markets with growing demand for minimally invasive spine procedures.
Leadership & Governance
Aurora Spine is founder-led, with executive leadership emphasizing product innovation, capital discipline, and surgeon-driven design. The company is governed by a board of directors and executive management team with experience in medical devices, spinal surgery markets, and commercialization of emerging healthcare technologies.
Key executives include:
- Trent J. Northcutt – President & Chief Executive Officer
- Ryan J. Northcutt – Chief Financial Officer
- Michael J. MacKay – Vice President of Sales
Public disclosures indicate leadership continuity and a strategic vision centered on expanding the company’s technology platform while managing growth within the constraints of a small-cap medical device operating environment.